Literature DB >> 15749199

Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction.

Quintino Parisi, Giuseppe G L Biondi-Zoccai, Antonio Abbate, Daniele Santini, Fortunata Vasaturo, Susanna Scarpa, Rossana Bussani, Antonio Maria Leone, Alessandro Petrolini, Furio Silvestri, Luigi M Biasucci, Alfonso Baldi.   

Abstract

We report hypoxia-inducible factor-1 (HIF-1) expression in myocardium of patients with recent acute myocardial infarction (AMI), supporting the hypothesis of HIF-1 as a possible mediator of response to ischemia. A potential diagnostic role of determining tissue expression of HIF-1 as a marker of ischemia, and potential therapeutic implications by trying to modulate HIF-1 activity in order to promote beneficial effects of HIF-1 related genes (e.g. expression of vascular endothelial growth factor (VEGF)) may derive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749199     DOI: 10.1016/j.ijcard.2003.11.038

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Authors:  Sylvie Négrier; Eric Raymond
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

2.  Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction.

Authors:  Jingbin Yu; Lei Zhang; Hui Zhang
Journal:  Exp Ther Med       Date:  2020-01-27       Impact factor: 2.447

3.  HIF-1α, MDM2, CDK4, and p16 expression in ischemic fasciitis, focusing on its ischemic condition.

Authors:  Yuichi Yamada; Izumi Kinoshita; Kenichi Kohashi; Hidetaka Yamamoto; Yuki Kuma; Takamichi Ito; Kenji Koda; Atsushi Kisanuki; Manabu Kurosawa; Michiko Yoshimura; Masutaka Furue; Yoshinao Oda
Journal:  Virchows Arch       Date:  2017-05-06       Impact factor: 4.064

4.  Surviving acute myocardial infarction: survivin expression in viable cardiomyocytes after infarction.

Authors:  D Santini; A Abbate; S Scarpa; F Vasaturo; G G Biondi-Zoccai; R Bussani; F De Giorgio; F Bassan; D Camilot; M P Di Marino; F Feroce; F Baldi; F Silvestri; F Crea; A Baldi
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

5.  Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.

Authors:  Anita Schwandt; Laura S Wood; Brian Rini; Robert Dreicer
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 6.  Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia.

Authors:  Ralph V Shohet; Joseph A Garcia
Journal:  J Mol Med (Berl)       Date:  2007-11-20       Impact factor: 4.599

Review 7.  Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments.

Authors:  Mi Xiang; Yingdong Lu; Laiyun Xin; Jialiang Gao; Chang Shang; Zhilin Jiang; Hongchen Lin; Xuqin Fang; Yi Qu; Yuling Wang; Zihuan Shen; Mingjing Zhao; Xiangning Cui
Journal:  Oxid Med Cell Longev       Date:  2021-05-18       Impact factor: 6.543

Review 8.  Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem?

Authors:  Christine J Pol; Alice Muller; Warner S Simonides
Journal:  Heart Fail Rev       Date:  2010-03       Impact factor: 4.214

9.  Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report.

Authors:  Chiara Valsuani; Olimpia Siclari; Andrea Camerini; Maria Laura Canale; Marianna Rondini; Sara Donati; Paolo Puccinelli; Gianna Tartarelli; Cheti Puccetti; Domenico Amoroso
Journal:  Cases J       Date:  2009-12-02

10.  Galectin-1 in early acute myocardial infarction.

Authors:  Suhail Al-Salam; Satwat Hashmi
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.